Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDAC

Br J Haematol. 2013 Aug;162(4):559-62. doi: 10.1111/bjh.12388. Epub 2013 May 21.
No abstract available

Keywords: Class I HDAC; HDAC6; histone deacetylase inhibitors; multiple myeloma.

Publication types

  • Comparative Study
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylation / drug effects
  • Antineoplastic Agents / pharmacology*
  • Apoptosis / drug effects*
  • Cell Line, Tumor / drug effects
  • Cell Line, Tumor / enzymology
  • Depsipeptides / pharmacology
  • Drug Screening Assays, Antitumor
  • Histone Deacetylase Inhibitors / pharmacology*
  • Histones / metabolism
  • Humans
  • Hydroxamic Acids / pharmacology
  • Indoles / pharmacology
  • Multiple Myeloma / enzymology
  • Multiple Myeloma / pathology*
  • Neoplasm Proteins / antagonists & inhibitors*
  • Panobinostat
  • Protein Processing, Post-Translational / drug effects
  • Pyrimidines / pharmacology
  • Tubulin / metabolism
  • Tumor Cells, Cultured / drug effects
  • Tumor Cells, Cultured / enzymology

Substances

  • 2-((1-(3-fluorophenyl)cyclohexyl)amino)-N-hydroxypyrimidine-5-carboxamide
  • Antineoplastic Agents
  • Depsipeptides
  • Histone Deacetylase Inhibitors
  • Histones
  • Hydroxamic Acids
  • Indoles
  • N-hydroxy-2-(1-phenylcycloproylamino)pyrimidine-5-carboxamide
  • Neoplasm Proteins
  • Pyrimidines
  • Tubulin
  • Panobinostat
  • romidepsin
  • ricolinostat